News | January 04, 2009

Carotid Endarterectomy Yields Better Short-Term Results than Carotid Stenting

January 5, 2009 - Carotid endarterectomy (CEA) yields better short-term results than carotid artery stenting (CAS) in patients with carotid artery disease, according to a 30-day outcomes report from the Society for Vascular Surgery (SVS) Vascular Registry for Carotid Procedures, published in the January 2009 issue of the Journal of Vascular Surgery.

Carotid artery disease is marked by stenosis (narrowing) of the carotid artery, located on either side of the neck, which supplies blood to the brain. Typically, this has been treated by performing an open repair surgery (CEA). An endovascular procedure (CAS) treats patients who are at risk for complications such as prior carotid artery surgery (i.e., CEA), neurological conditions (i.e., prior stroke), or exposure to radiation at the neck.

The SVS Outcomes Committee developed the Vascular Registry for Carotid Procedures in response to the 2005 Centers for Medicare and Medicaid Services National Coverage Decision on carotid artery stenting. The SVS Vascular Registry went live on July 2005, as the first societal registry to enroll CAS and CEA patients. Data are allocated to visit intervals of 30-day, six-month, one-year, and subsequent annual evaluations.

"As of December 26, 2007, 6,403 procedures with discharge data were entered by 287 providers at 56 centers," said Flora Siami, MPH, director, regulatory affairs and principal research scientist at New England Research Institutes Inc. in Watertown, MA. "In addition there were 1,450 CAS patients and 1,368 CEA patients with 30-day outcomes."

"Our primary outcome of interest was combined death, stroke, and myocardial infarction at 30-days post-procedure," said senior author Anton Sidawy, M.D., MPH, FACS, chief of vascular surgery at Veterans Affair Medical Center in Washington, D.C. and professor of surgery at both Georgetown and George Washington University Schools of Medicine in Washington, D.C. "The SVS Outcomes Committee also reviewed demographics, comorbidities, intra-operative complications."

"The majority of patients were treated because of atherosclerotic disease," said Dr. Sidawy. "In general, there was a greater proportion of CAS patients with pre-procedure lateralizing neurological symptoms, as well as higher prevalence of cardiac comorbidities compared with CEA patients."

Dr. Sidawy said after risk-adjustment for age, history of stroke, diabetes and the American Society of Anesthesiologists' grade (i.e., factors found to be significant confounders in outcomes using backwards elimination) logistic regression analysis suggested better outcomes following CEA. When CAS and CEA were compared in the treatment of atherosclerotic disease only, the difference in outcomes between the two procedures was more pronounced, with death/stroke/MI 6.42 percent after CAS vs. 2.62 percent following CEA, p

Dr. Sidawy explained, "Given the trend observed in the Vascular Registry, there is no justification to expand the use of CAS until the results of the randomized CREST trial are published providing level one evidence."

The SVS Vascular Registry for Carotid Procedures currently has 77 participating clinical facilities and more than 9,700 patients. The SVS Vascular Registry provides semi-annual institutional benchmarking reports to participating facilities on outcomes by procedure. New England Research Institutes, Inc. serves as the independent data coordinating center, maintaining the database and performing statistical analysis. The SVS designed the Vascular Registry with potential for expansion to procedures involving other vascular beds.

For more information: www.vascularweb.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init